Etofibrate
Etofibrate is a fibrate class medication primarily used to treat hyperlipidemia, which is an elevated level of lipids in the blood. It is a prodrug that is metabolized in the body to clofibric acid and nicotinic acid, both of which contribute to its lipid-lowering effects.
Mechanism of Action[edit]
Etofibrate works by activating peroxisome proliferator-activated receptor alpha (PPARα), which leads to an increase in the oxidation of fatty acids and a reduction in the production of triglycerides. This results in a decrease in very-low-density lipoprotein (VLDL) and an increase in high-density lipoprotein (HDL) levels.
Indications[edit]
Etofibrate is indicated for the treatment of various types of hyperlipidemia, including:
- Hypercholesterolemia
- Hypertriglyceridemia
- Mixed dyslipidemia
Pharmacokinetics[edit]
After oral administration, etofibrate is hydrolyzed to its active metabolites, clofibric acid and nicotinic acid. These metabolites are then absorbed into the bloodstream and exert their lipid-lowering effects. The drug is primarily excreted through the kidneys.
Side Effects[edit]
Common side effects of etofibrate include:
Contraindications[edit]
Etofibrate is contraindicated in patients with:
- Severe liver disease
- Severe kidney disease
- Gallbladder disease
- Known hypersensitivity to fibrates
Drug Interactions[edit]
Etofibrate may interact with other medications, including:
- Anticoagulants: Increased risk of bleeding
- Statins: Increased risk of myopathy and rhabdomyolysis
See Also[edit]
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
